Identification of a Novel Pyrazolo[3,4-d]pyrimidine Able To Inhibit Cell Proliferation of a Human Osteogenic Sarcoma in Vitro and in a Xenograft Model in Mice
- 11 October 2007
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 50 (23), 5579-5588
- https://doi.org/10.1021/jm061449r
Abstract
New pyrazolo[3,4-d]pyrimidines were synthesized and found to inhibit Src phosphorylation in a cell-free assay. Some of them significantly reduced the growth of human osteogenic sarcoma (SaOS-2) cells. The best compound, in terms of inhibitory properties toward both Src and SaOS-2 cells, was further investigated and found to reduce bone resorption when used to treat mouse osteoclasts, without interfering with normal osteoblast growth. Moreover, its metabolic stability prompted its study on a human SaOS-2 xenograft tumor model in nude mice, where the compound reduced significantly both the volume and weight of the tumor. These experimental findings make the new compound an interesting hit in the field of bone-related diseases.Keywords
This publication has 20 references indexed in Scilit:
- CD99 Acts as an Oncosuppressor in OsteosarcomaMolecular Biology of the Cell, 2006
- LDL induces Saos2 osteoblasts death via Akt pathways responsive to a neutral sphingomyelinase inhibitorJournal of Cellular Biochemistry, 2006
- Wnt Proteins Prevent Apoptosis of Both Uncommitted Osteoblast Progenitors and Differentiated Osteoblasts by β-Catenin-dependent and -independent Signaling Cascades Involving Src/ERK and Phosphatidylinositol 3-Kinase/AKTJournal of Biological Chemistry, 2005
- Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcomaOncogene, 2005
- Nongenotropic, Anti-Apoptotic Signaling of 1α,25(OH)2-Vitamin D3 and Analogs through the Ligand Binding Domain of the Vitamin D Receptor in Osteoblasts and OsteocytesOnline Journal of Public Health Informatics, 2005
- Emerging and potential therapies for osteoporosisExpert Opinion on Investigational Drugs, 2005
- Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone FormationThe Journal of cell biology, 2000
- A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivoBone, 1999
- Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice.JCI Insight, 1992
- Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in miceCell, 1991